Amgen Inc (AMGN) 167.91 $AMGN Are Biosimilars the Next

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 4:40 PM

Amgen Inc (AMGN) 167.91 $AMGN

Are Biosimilars the Next Big Thing in Biotech?
George Budwell, The Motley Fool - Motley Fool - Sat Apr 25, 6:06AM CDT
Biologics, or drugs developed from biological sources, have taken the pharma world by storm over the past decade or so. Five of the top 10 best-selling drugs in 2014, for example, were biologics indicated for either autoimmune disorders or cancer. ...
PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), AMGN: 167.91 (-1.26), TEVA: 64.41 (+1.16), ABBV: 66.07 (+1.82), NVS: 104.28 (-1.22)

Final Glance: Biotechnology companies
AP - Fri Apr 24, 7:08PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 103.69 (-1.52), AMGN: 167.91 (-1.26), CELG: 118.71 (+2.62)

CoLucid Pharmaceuticals on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 2:52PM CDT

AGN: 240.22 (+2.88), JNJ: 101.08 (+0.62), ENDP: 93.27 (-0.81), ALDR: 25.10 (-0.25), AVNR: 16.96 (unch), CLCD: (), RDHL: 14.70 (+0.02), PTX: 7.09 (-0.24), AMGN: 167.91 (-1.26), DEPO: 27.65 (+0.36), TEVA: 64.41 (+1.16), OFIX: 36.46 (+0.10)

Midday Glance: Biotechnology companies
AP - Fri Apr 24, 12:36PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 103.69 (-1.52), AMGN: 167.91 (-1.26), CELG: 118.71 (+2.62)

Early Glance: Biotechnology companies
AP - Fri Apr 24, 9:55AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 103.69 (-1.52), AMGN: 167.91 (-1.26), CELG: 118.71 (+2.62)

4 Nasdaq Stocks at All-Time Highs - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Apr 24, 9:27AM CDT
The Nasdaq touched an all-time on Thursday, breaching a record level achieved during the dot-com boom.
NVEE: 19.99 (+1.34), TSCO: 90.98 (-0.28), MNST: 141.78 (+1.42), BIIB: 401.71 (-28.57), DLTR: 81.14 (+0.13), GILD: 103.69 (-1.52), FB: 81.53 (-0.88), AMGN: 167.91 (-1.26), GOOGL: 573.66 (+16.20), ULTA: 157.08 (+0.09), MSFT: 47.87 (+4.53), INTU: 101.22 (-0.22), AAPL: 130.28 (+0.61)

Illumina's Earnings Set Positive Tone for Biotech
Cheryl Swanson, The Motley Fool - Motley Fool - Fri Apr 24, 9:02AM CDT
Illumina just lit up a lot of biotech portfolios. Thanks to record-breaking shipments of gene-sequencing instruments, total quarterly revenue surged 28% to $539 million.. Despite facing currency headwinds, the company handily beat the $524.45...
JNJ: 101.08 (+0.62), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), AMGN: 167.91 (-1.26), ILMN: 189.59 (-3.01), SNY: 51.75 (-0.01)

Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co.
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
VRX: 210.42 (+1.03), BMRN: 120.28 (-2.67), UTHR: 186.69 (-1.87), CLDX: 30.10 (+0.19), ACOR: 33.12 (-0.38), AFFX: 12.44 (-0.16), HSP: 87.61 (-0.05), OXGN: 1.48 (unch), MACK: 13.42 (-0.25), HBIO: 6.22 (+0.08), ECYT: 6.17 (-0.13), GEVA: 108.51 (+0.92), CYTR: 5.13 (-0.13), THRX: 17.92 (+0.46), FF: 11.18 (+0.03), MDXG: 9.81 (-0.39), EXEL: 3.08 (-0.02), VRTX: 133.20 (-2.62), NEO: 4.75 (-0.11), PFE: 35.27 (-0.09), INCY: 107.34 (-0.51), MYL: 76.06 (+2.37), AMGN: 167.91 (-1.26), ANIK: 38.35 (-0.32), ALKS: 62.26 (-1.19), ONTY: 1.74 (-0.05), CELG: 118.71 (+2.62), NBIX: 43.37 (-0.31), SGEN: 37.14 (-0.36), OGXI: 2.19 (+0.04), EBIO: 11.19 (+0.69), ABAX: 63.62 (+0.31), GILD: 103.69 (-1.52), GERN: 4.30 (-0.03), HAE: 43.35 (+0.74), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16), PCRX: 85.07 (+0.80)

InsiderInsights.com Daily Round Up 4/23/15: GE, OMN, COCP, AGCO
InsiderInsights - at Seeking Alpha - Fri Apr 24, 7:53AM CDT

STFC: 23.91 (unch), GE: 26.80 (-0.05), OMN: 8.37 (+0.04), AGCO: 48.31 (-0.56), SAM: 265.97 (+2.12), AMGN: 167.91 (-1.26), ILMN: 189.59 (-3.01), NXRT: 13.97 (+0.10), BDCV: 5.09 (+0.05), MPWR: 49.96 (-3.55), WCIC: 24.13 (+0.26), ADS: 307.44 (-2.47), KMX: 69.97 (-0.75), SVVC: 15.34 (+0.04), ALNY: 119.01 (+0.29), GRPN: 7.11 (-0.04), UCTT: 6.26 (+0.60)

Biotech Beat: Amgen And Gilead News
Young Money Monsters - at Seeking Alpha - Fri Apr 24, 2:29AM CDT
By Jacob Urban There are many things that cause a stock to move: acquisition rumors, news stories (both positive and negative), earnings releases, analyst upgrades/downgrades, ETF-forced movement, changes in the commodities market, and macro events...
GILD: 103.69 (-1.52), AMGN: 167.91 (-1.26)

Amgen, Inc. Earnings: 4 Things You Probably Overlooked
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 23, 12:29PM CDT
Source: Amgen, Flickr. On Tuesday, biotech behemoth Amgen reported its first-quarter earnings results and continued what's been a welcome streak of market-topping reports. For the quarter, Amgen announced revenue of $5.03 billion, an 11%...
AMGN: 167.91 (-1.26)

Is Amgen Inc.'s Dividend Sustainable?
Brian Feroldi, The Motley Fool - Motley Fool - Thu Apr 23, 11:03AM CDT
Buying and holding dividend-paying stocks has proven to be a terrific strategy for long-term investors. Companies with the ability to raise their dividends over time can become compounding machines and provide shareholders with a reliable source of...
GILD: 103.69 (-1.52), AMGN: 167.91 (-1.26)

AbbVie raises outlook as Humira again delivers earnings beat
By MATTHEW PERRONE - AP - Thu Apr 23, 9:48AM CDT
WASHINGTON (AP) — Drugmaker AbbVie is raising its full-year earnings guidance after reporting better-than-expected first quarter adjusted results on continued growth of its blockbuster anti-inflammatory drug Humira.
JNJ: 101.08 (+0.62), SHPG: 255.11 (-0.26), AMGN: 167.91 (-1.26)

Amgen: Growth Is Accelerating
Bret Jensen - at Seeking Alpha - Thu Apr 23, 9:34AM CDT

AMGN: 167.91 (-1.26)

The Zacks Analyst Blog Highlights: Amgen, Medicines, Athersys and Alnylam - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 8:30AM CDT
The Zacks Analyst Blog Highlights: Amgen, Medicines, Athersys and Alnylam
ALNY: 119.01 (+0.29), MDCO: 27.41 (+0.09), AMGN: 167.91 (-1.26), ATHX: 1.29 (-0.03)

Amgen Flexes Its Earnings Muscle
Dan Strack - at Seeking Alpha - Thu Apr 23, 7:34AM CDT

AMGN: 167.91 (-1.26)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Puori Protein Transparency Pays Off Amid Lead Scare

Puori's Moment of Reckoning The world of nutritional supplements is no stranger to controversy, but when Puori found itself caught in the storm of the Consumer Reports investigation last year, it chose a road less traveled: transparency and accountability. Faced with alarming news that over two-thirds of tested protein powders exceeded California's Proposition 65 lead...

Oracle Announces AI-Driven QuickStart Platform Launch

NetSuite's AI-First Step into the Market Well, here's the NYSE stirring the pot with Oracle NetSuite's fresh announcement—an AI-first platform called QuickStart. Sounds like they've got their sights set on early-stage tech startups, banking on those little guys to plug into AI tools they've already got in their toolkit. Claude, ChatGPT—these aren't new kids on the...

Wagner Logistics Gears Up for Major Expansion in Liberty

Imagine waking up to news like this: Wagner Logistics is laying down some serious roots in Liberty, MO. They’ve snagged a deal with a local manufacturer that’s got them renting out over 830,000 square feet of warehouse space. Seems Wagner's got a knack for living large. More Than Just a Warehouse Gig Wagner's not just popping up another dusty shelf space; they're...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

FCS Drives Key FDA Approvals in Cancer Treatment

Florida Cancer Specialists: Changing the Cancer Treatment Game Some organizations toot their horns, but every now and then, a group truly shakes up the playing field. Take Florida Cancer Specialists & Research Institute (FCS), for instance. Over years of relentless research, FCS has nailed its role in securing two significant FDA approvals aimed at expanding treatment...

Montesodi 2023: A Fresh Chapter in Chianti Excellence

A Glass Filled with History and Nature's Whimsy When you pour a glass of Montesodi 2023, you’re not just tasting wine but a story—a saga that blends Tuscany’s rich vineyard history with last year's unpredictable weather. Marchesi Frescobaldi, a name that’s seen it all over its thousand years, has once again shown us how resilience and tradition can marry with...

AI-Powered Travel Transformation in Norway Revealed

AI-Driven Travel Meets Norway's Authentic Charm Well, folks, once again we're staring down the barrel of technology going full throttle in the travel game. Mindtrip, the savvy AI-powered travel platform, just inked a deal with the Norwegian Travel Cluster. It's their first tango in Europe, and they're not dipping their toes—they're diving headfirst into the icy fjords....

WIN Expands Leadership Amidst Rapid Growth Surge

Why WIN's Leadership Shake-Up Matters Change is afoot at the fertility and family support powerhouse WIN, and there's no mistaking the bold handwriting on the wall. As they swell towards supporting one million families, WIN's revamping their leadership table with three key players aimed at pushing the envelope further than before. They've got Claudio Stefan, Stacey...

Gourmia Introduces Ceramic-Coated Air Fryer at Costco

A New Era for Home Cooking with Gourmia Stepping into the kitchen appliances arena with a dash of innovation, Gourmia has launched its first ceramic-coated air fryer, and it’s weaving its way exclusively onto the shelves of Costco. Now, it’s not just about frying anymore; it’s about adding style, efficiency, and a touch of healthy living to your countertop. But much...